Yüklüyor......
Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia
Recent developments in the management of chronic lymphocytic leukemia (CLL) have moved the standard of care away from chemoimmunotherapy to targeted agents such as oral kinase inhibitors or BCL-2 antagonists, alone or in combination with anti-CD20 antibodies. Two different treatment approaches have...
Kaydedildi:
| Yayımlandı: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
American Society of Hematology
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7727567/ https://ncbi.nlm.nih.gov/pubmed/33275717 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2020000120 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|